Asian Study to Investigate Safety and Efficacy of Optimized Dosing of Advagraf in Kidney Transplantation
Status:
Completed
Trial end date:
2016-12-22
Target enrollment:
Participant gender:
Summary
Primary purpose of this study is to compare renal function between subjects receiving
optimized dose Advagraf® over 52 weeks after kidney transplantation and subjects receiving
standard dose Advagraf®. Pilot results of safety and efficacy in optimized dose Advagraf®
over 52 weeks after kidney transplantation will also be obtained.